Improving immunogenicity and effectiveness of influenza vaccine in older adults

References

• Walford RL. The immunologic theory of aging. Munksgaard Press, Copenhagen, Denmark (1969).
   Google Scholar
• Grolleau-Julius A, Ray D, Yung RL. The role of epigenetics in aging and autoimmunity. Clin. Rev. Allergy Immunol.39(1), 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Ksiazek K. Oxidative stress as an universal cause of aging – from human somatic cells to the unicellular yeast and bacteria. Postepy. Biochem.56(3), 260–268 (2010).
   PubMedGoogle Scholar
• Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G. Oxidative stress and aging. J. Nephrol.23(Suppl. 15), S29–S36 (2010).
   PubMedGoogle Scholar
• Sansoni P, Cossarizza A, Brianti V et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood82(9), 2267–2273 (1993).
   Google Scholar
• Vitale M, Zamai L, Neri LM et al. The impairment of natural killer function in the healthy aged is due to a postbinding deficient mechanism. Cell Immunol.145(1), 1–10 (1992).
   PubMed Web of Science ®Google Scholar
• Ogata K, Yokose N, Tamura H et al. Natural killer cells in the late decades of human life. Clin. Immunol. Immunopathol.84(3), 269–275 (1997).
   PubMedGoogle Scholar
• Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol.20, 825–852 (2002).
   PubMed Web of Science ®Google Scholar
• Zissel G, Schlaak M, Muller-Quernheim J. Age-related decrease in accessory cell function of human alveolar macrophages. J. Investig. Med.47(1), 51–56 (1999).
   PubMed Web of Science ®Google Scholar
• Kohut ML, Senchina DS, Madden KS, Martin AE, Felten DL, Moynihan JA. Age effects on macrophage function vary by tissue site, nature of stimulant, and exercise behavior. Exp. Gerontol.39(9), 1347–1360 (2004).
   PubMed Web of Science ®Google Scholar
• Della Bella S, Bierti L, Presicce P et al. Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin. Immunol.122(2), 220–228 (2007).
   PubMed Web of Science ®Google Scholar
• Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng T. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum. Immunol.70(10), 777–784 (2009).
   PubMed Web of Science ®Google Scholar
• Agrawal A, Agrawal S, Cao JN, Su H, Osann K, Gupta S. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J. Immunol.178(11), 6912–6922 (2007).
   PubMed Web of Science ®Google Scholar
• Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell3(4), 161–167 (2004).
   PubMed Web of Science ®Google Scholar
• Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol.169(9), 4697–4701 (2002).
   PubMed Web of Science ®Google Scholar
• Sambhara S, Kurichh A, Miranda R et al. Severe impairment of primary but not memory responses to influenza viral antigens in aged mice: costimulation in vivo partially reverses impaired primary immune responses. Cell Immunol.210(1), 1–4 (2001).
   PubMedGoogle Scholar
• Sambhara S, Kurichh A, Miranda R et al. Enhanced immune responses and resistance against infection in aged mice conferred by Flu-ISCOMs vaccine correlate with up-regulation of costimulatory molecule CD86. Vaccine16(18), 1698–1704 (1998).
   PubMedGoogle Scholar
• Linton PJ, Li SP, Zhang Y, Bautista B, Huynh Q, Trinh T. Intrinsic versus environmental influences on T-cell responses in aging. Immunol. Rev.205, 207–219 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR. Dysregulation of human Toll-like receptor function in aging. Ageing Res. Rev.10(3), 346–353 (2011).
   PubMed Web of Science ®Google Scholar
• Panda A, Qian F, Mohanty S et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol.184(5), 2518–2527 (2010).
   PubMed Web of Science ®Google Scholar
• Van Duin D, Allore HG, Mohanty S et al. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J. Infect. Dis.195(11), 1590–1597 (2007).
   PubMed Web of Science ®Google Scholar
• Van Duin D, Mohanty S, Thomas V et al. Age-associated defect in human TLR-1/2 function. J. Immunol.178(2), 970–975 (2007).
   PubMed Web of Science ®Google Scholar
• Aspinall R, Andrew D. Thymic involution in aging. J. Clin. Immunol.20(4), 250–256 (2000).
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat. Immunol.5(2), 133–139 (2004).
   PubMed Web of Science ®Google Scholar
• Flores KG, Li J, Sempowski GD, Haynes BF, Hale LP. Analysis of the human thymic perivascular space during aging. J. Clin. Invest.104(8), 1031–1039 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenbery SA, Sportes C, Ahmadzadeh M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother.29(3), 313–319 (2006).
   PubMedGoogle Scholar
• Aggarwal S, Gupta S. Increased activity of caspase 3 and caspase 8 in anti-Fas-induced apoptosis in lymphocytes from ageing humans. Clin. Exp. Immunol.117(2), 285–290 (1999).
   PubMedGoogle Scholar
• Aggarwal S, Gupta S. Increased apoptosis of T cell subsets in aging humans: altered expression of Fas (CD95), Fas ligand, Bcl-2, and Bax. J. Immunol.160(4), 1627–1637 (1998).
   PubMedGoogle Scholar
• Timm JA, Thoman ML. Maturation of CD4+ lymphocytes in the aged microenvironment results in a memory-enriched population. J. Immunol.162(2), 711–717 (1999).
   PubMedGoogle Scholar
• Plowden J, Renshaw-Hoelscher M, Gangappa S, Engleman C, Katz JM, Sambhara S. Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol.229(2), 86–92 (2004).
   PubMedGoogle Scholar
• Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol.75(24), 12182–12187 (2001).
   PubMed Web of Science ®Google Scholar
• Naylor L, Li G, Vallejo AN et al. The influence of age on T cell generation and TCR diversity. J. Immunol.174(11), 7446–7452 (2005).
   PubMed Web of Science ®Google Scholar
• Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, Blackman MA. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J. Exp. Med.205(3), 711–723 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao L, Sun L, Wang H, Ma H, Liu G, Zhao Y. Changes of CD4+CD25+Foxp3+ regulatory T cells in aged Balb/c mice. J. Leukoc. Biol.81(6), 1386–1394 (2007).
   PubMedGoogle Scholar
• Rosenkranz D, Weyer S, Tolosa E et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol.188(1–2), 117–127 (2007).
   PubMed Web of Science ®Google Scholar
• Gregg R, Smith CM, Clark FJ et al. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin. Exp. Immunol.140(3), 540–546 (2005).
   PubMed Web of Science ®Google Scholar
• Buffa S, Bulati M, pellicano M et al. B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology DOI: 10.1007/s10522-011-9353-4 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Gibson KL, Wu YC, Barnett Y et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell8(1), 18–25 (2009).
   PubMed Web of Science ®Google Scholar
• Han S, Yang K, Ozen Z et al. Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice. J. Immunol.170(3), 1267–1273 (2003).
   PubMed Web of Science ®Google Scholar
• Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect. Dis. Clin. North Am.18(1), 141–155 (2004).
   PubMed Web of Science ®Google Scholar
• Hampson AW, Mackenzie JS. The influenza viruses. Med. J. Aust.185(10 Suppl.), S39–S43 (2006).
   PubMed Web of Science ®Google Scholar
• Virelizier JL, Postlethwaite R, Schild GC, Allison AC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. I. Thymus dependence of antibody formation and thymus independence of immunological memory. J. Exp. Med.140(6), 1559–1570 (1974).
   PubMed Web of Science ®Google Scholar
• Ennis FA, Rook AH, Qi YH et al. HLA restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines. Lancet2(8252), 887–891 (1981).
   PubMed Web of Science ®Google Scholar
• Jenne DE, Tschopp J. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation. Immunol. Rev.103, 53–71 (1988).
   PubMed Web of Science ®Google Scholar
• Pasternack MS, Eisen HN. A novel serine esterase expressed by cytotoxic T lymphocytes. Nature314(6013), 473–475 (1985).
   Google Scholar
• Hosaka Y, Sasao F, Yamanaka K, Bennink JR, Yewdell JW. Recognition of noninfectious influenza virus by class I-restricted murine cytotoxic T lymphocytes. J. Immunol.140(2), 606–610 (1988).
   PubMed Web of Science ®Google Scholar
• Francis T Jr. Vaccination against influenza. Bull. World Health Organ.8(5–6), 725–741 (1953).
   PubMedGoogle Scholar
• Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr. Top. Microbiol. Immunol.333, 43–82 (2009).
   PubMedGoogle Scholar
• Fiore AE, Uyeki TM, Broder K et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm. Rep.59(RR-8), 1–62 (2010).
   PubMedGoogle Scholar
• Gorse GJ, O’Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine21(17–18), 2133–2144 (2003).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med.357(14), 1373–1381 (2007).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N. Engl. J. Med.348(14), 1322–1332 (2003).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect. Dis.7(10), 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Jackson ML, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet372(9636), 398–405 (2008).
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Briggs D, Brown CM et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm. Rep.59(RR-2), 1–9 (2010).
   PubMedGoogle Scholar
• Fischer M, Lindsey N, Staples JE et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.59(RR-1), 1–27 (2010).
   PubMedGoogle Scholar
• Gross PA. Review: inactivated vaccines provide the greatest protection against influenza in healthy persons. ACP J. Club136(3), 103 (2002).
   PubMedGoogle Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine24(8), 1159–1169 (2006).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin. Pharmacol. Ther.82(6), 740–744 (2007).
   PubMed Web of Science ®Google Scholar
• Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging28(2), 93–106 (2011).
   PubMed Web of Science ®Google Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine26(26), 3209–3222 (2008).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines10(4), 447–462 (2011).
   PubMed Web of Science ®Google Scholar
• De Donato S, Granoff D, Minutello M, Lecchi G et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine17(23–24), 3094–3101 (1999).
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine17(2), 99–104 (1999).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol.17(2), 135–140 (2001).
   PubMed Web of Science ®Google Scholar
• Balli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA106(19), 7962–7967 (2009).
   PubMedGoogle Scholar
• Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol.17(11), 1817–1817 (2010).
   PubMedGoogle Scholar
• Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA106(10), 3877–3882 (2009).
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine26(4), 552–561 (2008).
   PubMed Web of Science ®Google Scholar
• Higgins DA, Carlson JR, Van Nest G. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine14(6), 478–484 (1996).
   PubMed Web of Science ®Google Scholar
• Baras B, Bouveret N, Devaster JM et al. A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir. Viruses2(6), 251–260 (2008).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 580–589 (2007).
   PubMedGoogle Scholar
• Moris P, van der Most R, Leroux-Roels I et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol.31(3), 443–454 (2011).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels, Roman F, Forqus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine28(3), 849–857 (2010).
   PubMedGoogle Scholar
• Heijimans S, De Meulemeester M, Reynders P et al. Immunogenicity profile of a 3.75-µg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J. Infect. Dis.203(8), 1054–1062 (2011).
   PubMedGoogle Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin. Infect. Dis.51(6), 668–677 (2010).
   PubMed Web of Science ®Google Scholar
• Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine25(44), 7656–7663 (2007).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med.166(10), 1121–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Palache AM, Beyer WE, Sprenger MJ et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine11(1), 3–9 (1993).
   PubMed Web of Science ®Google Scholar
• Chen WH, Cross AS, Edelman R et al. Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. Vaccine29(16), 2865–2873 (2011).
   PubMed Web of Science ®Google Scholar
• Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev. Vaccines9(10), 1127–1133 (2010).
   PubMed Web of Science ®Google Scholar
• CDC. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use – United States. MMWR Morb. Mortal. Wkly Rep.59(16), 485–486 (2010).
   PubMedGoogle Scholar